Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis

Su Jen Chua* (Corresponding Author), Ben W. Mol, Salvatore Longobardi, Raoul Orvieto, Christos A. Venetis, Monica Lispi, Ashleigh Storr, Thomas D’Hooghe

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Live birth has increasingly been identified as the standard clinical approach to measure the success of medically assisted reproduction (MAR). However, previous analyses comparing biosimilar preparations of follitropin alfa versus the reference product (GONAL-f®, Merck KGaA, Darmstadt, Germany or GONAL-f® RFF; EMD Serono, Inc., Rockland, MA), have had insufficient power to detect differences in clinically meaningful outcomes such as live birth.
Original languageEnglish
Article number51
Number of pages13
JournalReproductive Biology and Endocrinology
Volume19
Issue number1
Early online date2 Apr 2021
DOIs
Publication statusPublished - 2021

Keywords

  • Biosimilar
  • Follitropin alfa
  • IVF
  • Ovarian stimulation
  • r-hFSH

Fingerprint

Dive into the research topics of 'Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this